Fluconazole 150 mg Tablets

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are rapidly and almost completely absorbed; therefore, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vulvovaginal candidiasis: Administer fluconazole 150 mg orally as a single dose. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg once on the first day, followed by 200 mg once daily from the next day. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined according to the clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg once on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment should be determined based on the clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this medicine once daily indefinitely after the patient has completed all initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk of fungal infections due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily according to the patient's level of risk for fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those undergoing bone marrow transplantation who are expected to have severe or prolonged neutropenia. In these patients, 400 mg should be administered 5-6 days before the anticipated onset of neutropenia and continued for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until new, uninfected nails have grown). It usually takes 3-6 months for a new fingernail to grow and 6-12 months for a toenail; growth rates may vary by individual and age. In some cases, the fingernails or toenails may remain damaged after successful treatment with long-term administration. Dermatophyte infections of the skin, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this medicine is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks depending on the course of the infection. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose should be administered; if renal impairment is present (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This medicine is excreted primarily in the urine unchanged. No dose adjustment is necessary for a single dose; however, when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the following day as follows: Creatinine clearance (mL/min) > 50: 100 % of the usual dose Creatinine clearance (mL/min) ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients on hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, the dose should be reduced according to creatinine clearance.

This drug should not be administered to certain patients. First, individuals with allergies to this drug or similar components should not use it. Second, pregnant women or those who may become pregnant and nursing mothers should not take this medication. Third, it should not be taken with certain specific medications due to the potential for risk when co-administered. There are also patients who need caution while using this medication. Those with a history of allergies or issues with kidney or liver function should use it carefully. Individuals with heart disease or electrolyte imbalances who are at risk for arrhythmias also need special attention. Furthermore, if this drug is used in conjunction with certain medications, physician monitoring is necessary. Generally, this drug is safe, but it can rarely affect blood, liver, and kidneys. Symptoms such as headache, dizziness, indigestion, rash, and various side effects may occur, and if any abnormal symptoms appear, immediate notification is necessary. Particularly in cases of liver function abnormalities, if liver enzyme levels rise during treatment, careful consideration is needed about whether to continue using this drug. There is a risk of severe skin reactions, so attention should be paid to skin changes. Use of this drug during pregnancy may be harmful to the fetus, so contraception is essential, and it should not be used during pregnancy. In breastfeeding cases, this medication can be transmitted through breast milk, so it should be avoided. For children under 6 months of age, safety has not been established, so it should only be used if necessary. Caution is advised when driving or operating machinery due to the risk of dizziness or seizures. In cases of overdose, hallucinations or abnormal behavior can occur, necessitating immediate contact with a medical institution and supportive care if needed. This medication is primarily excreted through urine, with some removal possible via hemodialysis. This drug has many interactions with other medications, so if other medications are being taken, it is essential to consult a physician or pharmacist. Special caution is needed when co-administering with heart-related drugs, anticoagulants, antidepressants, immunosuppressants, and antibiotics.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, taste disturbance, tremor, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, hepatic failure, hepatocyte necrosis, hepatitis, hepatocellular damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, malaise, weakness, fever, adrenal insufficiency, changes in hematological function test results, hepatic impairment, renal dysfunction, abnormal blood tests, electrolyte abnormalities, adrenal cortical insufficiency, hepatic necrosis, increased liver enzymes, ventricular tachycardia, ventricular fibrillation, heart block, bradycardia, side effects related to increased plasma concentration, bleeding tendency, respiratory depression, pseudotumor cerebri, adrenal cortical insufficiency, hallucinations, agitated behavior

This medication should be stored in a tightly sealed container to prevent air and moisture from entering. The recommended storage temperature is between 1 and 30 degrees Celsius. Storing it this way ensures the medication’s effectiveness is safely maintained.

Appearance

Pink rectangular tablets

Package unit

30 tablets/bottle